A Study to Evaluate the Safety, Tolerability, Pharmacokinetics of RAY1216 and the Effect of Food on RAY1216 Pharmacokinetics in Healthy Adult Participants
Overview
- Phase
- Phase 1
- Intervention
- RAY1216 dose 9
- Conditions
- COVID-19 (Coronavirus Disease 2019)
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) in single ascending dose
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is double-blind,randomized, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety, tolerability and drug-drug interaction of RAY1216, and the effect of food on RAY1216 Pharmacokinetics.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signature of a dated Informed Consent Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
- •Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
- •Subjects (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product.
- •Males and female subjects between 18-50 years (Both inclusive). Body weight is no less than 50 kg in males and no less than 45 kg in females. Body mass index (BMI) 18≤BMI≤28 kg/m2; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
- •Physical condition and vital signs: Normal or abnormality has no clinical significance.
Exclusion Criteria
- •Known hypersensitivity and/or allergy to some drugs and food, especially for the composition that is similar to the investigative product;
- •The average daily smoking are more than 5 cigarettes within 3 months prior to screening.
- •Known history of drug or alcohol abuse.(defined as consumption of 14 units of alcohol per week: 1 unit = 285 ml of beer; or the equivalent of 25 ml of spirit, or 100 ml of wine )
- •Subjects who donated blood or bleeding profusely (\> 400 mL) in the 3 months preceding study screening.
- •Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs, include a history of frequent nausea or vomit causes by any etiology.
- •History or presence of any disease or condition known to increase the risk of bleeding , eg. acute gastritis, duodenal ulcer, etc.
- •Participated in another clinical research study and received any investigational products within 3 months prior to dosing.
- •History of having any special food (including dragon fruit, mango, grapefruit, etc.), strenuous exercises, or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 7 days prior to screening.
- •Inability to consume the food provided in the study ( a high fat diet).This requirement only applies to subjects under fed condition.
- •Presence of clinically significant abnormalities in ECG or QTcF\>450ms
Arms & Interventions
RAY1216 dose 9（food effect）
food effect on single dose
Intervention: RAY1216 dose 9
RAY1216 dose 10（food effect）
food effect on single dose
Intervention: RAY1216 dose 10
RAY1216 dose 6
MAD
Intervention: RAY1216 dose 6
RAY1216 dose 7
MAD
Intervention: RAY1216 dose 7
RAY1216 dose 8
MAD
Intervention: RAY1216 dose 8
RAY1216 dose 1
SAD
Intervention: RAY1216 dose 1
RAY1216 dose 2
SAD
Intervention: RAY1216 dose 2
RAY1216 dose 3
SAD
Intervention: RAY1216 dose 3
RAY1216 dose 4（DDI）
drug-drug interaction
Intervention: RAY1216 dose 4 &ritonavir
RAY1216 dose 5
MAD
Intervention: RAY1216 dose 5
Outcomes
Primary Outcomes
Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) in single ascending dose
Time Frame: Day 1 to Day 5
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported
Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) in multiple ascending dose
Time Frame: Day 1 to Day 9
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported
Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) in food effect part
Time Frame: Day 1 to Day 21
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported
Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE) in DDI part
Time Frame: Day 1 to Day 15
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported
Secondary Outcomes
- To determine the single and multiple oral dose pharmacokinetic profiles of RAY1216(Cmax)(Day 1 to Day 9)
- To determine the effect of food on the PK of RAY1216 single dose(AUC0-∞)(Day 1 to Day 21)
- To determine the effect of food on the PK of RAY1216 single dose(Cmax)(Day 1 to Day 21)
- To determine the single and multiple oral dose pharmacokinetic profiles of RAY1216(Cmin)(Day 1 to Day 9)
- To investigate the effect of Ritonavir on the pharmacokinetics of RAY1216(Cmax)(Day 1 to Day 15)
- To investigate the effect of Ritonavir on the pharmacokinetics of RAY1216(AUC0-∞)(Day 1 to Day 15)